Research reference · 10 mg vial

BPC-157 (10 mg Vial) Dosage Protocol

Written by PeptideDosages Editorial Team Published Updated

This BPC-157 dosage chart converts a 10 mg vial reconstituted with 3.0 mL of bacteriostatic water into a 3.33 mg/mL concentration. It shows the exact U-100 syringe measurements for a 200–600 mcg community-reported calculation sequence. Human research has not established that sequence as a validated BPC-157 treatment protocol.[1][5]

On this page
  1. Quick reference
  2. Dosage chart and four steps
  3. Supplies needed
  4. Vial and research context
  5. BPC-157 10 mg Vial and Research Context
  6. BPC-157 Dosage Protocol Overview
  7. Human BPC-157 Dosage Evidence
  8. How BPC-157 Is Proposed to Work
  9. BPC-157 for Tendon, Ligament, and Muscle Research
  10. Gut Health, Wound Healing, and Tissue Repair Research
  11. BPC-157 Side Effects, Safety, and Regulatory Limits
  12. BPC-157 Storage After Reconstitution
  13. U-100 Syringe Measurements and Injection Technique
  14. BPC-157 10 mg vs Other Vial Strengths
  15. BPC-157 Dosage Questions
  16. Important Research Note
  17. BPC-157 Dosage Guide by Route and Research Question
  18. BPC-157 Injection Dosage and Unit Math
  19. Questions About BPC-157 Dosage Ranges and Stacking
  20. References
  21. Related research, protocols, and guides

BPC-157 Quick Reference (10 mg Vial)

Vial contents
10 mg BPC-157
Final volume
3 mL
Concentration
3.33 mg/mL
One U-100 unit
33.33 mcg in 0.01 mL
BPC-157 (10 mg Vial) Dosage Protocol peptide vial

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read BPC-157 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

BPC-157 Dosage Chart

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 6 units (0.06 mL)
Weeks 3–4 400 mcg (0.4 mg) 12 units (0.12 mL)
Weeks 5–8+ 600 mcg (0.6 mg) 18 units (0.18 mL)

Community-reported use: The table uses a once-daily subcutaneous frequency to keep the vial-use and supply calculations reproducible. It is not a clinically validated human BPC-157 dosing schedule. Animal doses cannot be converted directly into a human injection protocol, and published human evidence does not validate these 200–600 mcg rows.[1][5]

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Research reference only: The chart combines community-reported amounts with transparent concentration and syringe-conversion math for a 10 mg vial. It is not a validated human treatment schedule or medical advice.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (BPC-157, 10 mg each):
    • 8 weeks: approximately 3 vials required (25.2 mg used)
    • 12 weeks: approximately 5 vials required (42 mg used)
    • 16 weeks: approximately 6 vials required (58.8 mg used)
  • Insulin Syringes (U-100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 8 weeks (3 vials): 9 mL — 1 bottle required (10 mL each)
    • 12 weeks (5 vials): 15 mL — 2 bottles required (10 mL each)
    • 16 weeks (6 vials): 18 mL — 2 bottles required (10 mL each)
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
    • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
    • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)
BPC-157 10 mg

BPC-157 10 mg

View Supplier
U-100 syringes

U-100 syringes

View Supplier
Bacteriostatic water

Bacteriostatic water

View Supplier
Alcohol swabs

Alcohol swabs

View Supplier

BPC-157 Vial and Research Context

  • Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
  • Typical daily range: 200–600 mcg once daily (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

BPC-157, or Body Protection Compound 157, is a synthetic 15-amino-acid gastric pentadecapeptide studied in laboratory models of tendon, ligament, muscle, gastrointestinal, and wound repair.[1][2][7] Systematic reviews conclude that nearly all efficacy findings remain preclinical; limited human reports and a two-participant intravenous pilot do not establish a subcutaneous dose, treatment benefit, or long-term safety profile.[1][4]

BPC-157 10 mg Vial and Research Context

A 10 mg vial contains 10,000 mcg of BPC-157. Adding 3.0 mL gives 3,333 mcg/mL, so one U-100 unit (0.01 mL) contains about 33.3 mcg. The vial strength changes the concentration, syringe markings, vial coverage, and supply quantities; it does not create a scientifically established dose.

  • 200 mcg: 0.06 mL, or 6 U-100 units.
  • 400 mcg: 0.12 mL, or 12 U-100 units.
  • 600 mcg: 0.18 mL, or 18 U-100 units.
  • Vial coverage by mass: 50 amounts at 200 mcg, 25 at 400 mcg, or about 16 full amounts at 600 mcg, before accounting for handling loss or a formulation-specific discard date.

BPC-157 Dosage Protocol Overview

This BPC-157 dosage protocol is an educational measurement model built around the existing 10 mg vial chart. It is important to separate the page’s arithmetic from the underlying evidence: systematic reviews identify a large animal and laboratory literature, but only sparse human evidence and no validated subcutaneous dosage schedule.[1][2]

  • Primary calculation: 10 mg reconstituted to 3.0 mL equals 3.33 mg/mL.
  • Displayed amount range: 200–600 mcg per administration, presented as community-reported use rather than a clinical recommendation.
  • Displayed route: Subcutaneous injection for calculation consistency; published human research does not establish this route and schedule as effective.
  • Evidence ceiling: Musculoskeletal, gut, wound-healing, and anti-inflammatory claims are driven mainly by preclinical models.[1][2][8]
  • Regulatory context: BPC-157 is not FDA-approved, and the FDA has identified substantial gaps in clinical safety and product-characterization information.[5]

Human BPC-157 Dosage Evidence

Human BPC-157 research is too limited to establish a recommended dose, injection frequency, cycle length, or therapeutic range. A 2025 orthopedic systematic review screened 544 records and included 36 studies, of which 35 were preclinical and one was a small clinical report.[1] That imbalance matters: an animal dose expressed in micrograms per kilogram is not a human conversion rule.

A 2025 intravenous pilot involved only two adults who received 10 mg and 20 mg infusions on consecutive study days. The authors reported no measured biomarker changes or participant-reported side effects, but the sample was far too small to characterize uncommon risks, longer-term safety, subcutaneous administration, or treatment efficacy.[4] A registered Phase I oral study also does not validate the injection chart on this page.[6]

Clinics, forums, and community discussions were reviewed privately to understand the commonly repeated 200–600 mcg range. Those sources are inconsistent, are not cited as scientific evidence, and do not convert anecdotal popularity into a clinically supported BPC-157 dose.

How BPC-157 Is Proposed to Work

BPC-157 is often described as a stable gastric pentadecapeptide because its amino-acid sequence is associated with a gastric protein fragment. Laboratory studies examine several overlapping pathways rather than one confirmed human mechanism. Reviews discuss nitric oxide signaling, vascular function, angiogenesis, fibroblast migration, collagen organization, growth-factor expression, and cellular stress responses.[2][7][8]

  • Nitric oxide system: Animal and cellular research links BPC-157 with modulation of nitric oxide pathways and vascular responses.[9][10]
  • Angiogenesis: A muscle and tendon model reported VEGF-associated vascular changes during healing, but this remains preclinical evidence.[12]
  • Tendon and ligament repair: Rat studies report structural, biomechanical, and functional changes after experimentally created injuries.[11][13]
  • Drug disposition: Rat and dog pharmacokinetic experiments reported rapid metabolism and an elimination half-life under 30 minutes for the parent peptide; those findings do not define human dosing.[3]

BPC-157 for Tendon, Ligament, and Muscle Research

Much of the search interest around BPC-157 peptide dosage relates to tendon, ligament, muscle, and injury recovery. The evidence is intriguing but easy to overstate. A recent systematic review found improvements across animal musculoskeletal models while emphasizing the near-absence of controlled human trials.[1] Narrative reviews reach a similar conclusion: laboratory outcomes do not yet establish human effectiveness or a reliable safety profile.[2][16][17]

  • A rat medial collateral ligament transection study reported functional, biomechanical, macroscopic, and histologic improvements with experimental BPC-157 administration.[11]
  • A rat rotator cuff model reported improved tendon-to-bone healing outcomes.[13]
  • A rat myotendinous-junction study reported restoration across several injury assessments.[14]
  • A rat muscle-to-bone detachment study reported recovery measures across imaging, biomechanical, and functional endpoints.[15]

These experiments used different species, injury models, routes, and mass-per-body-weight regimens. They should not be combined into a single human BPC-157 injection protocol.

Gut Health, Wound Healing, and Tissue Repair Research

BPC-157 originated in gastrointestinal and cytoprotection research, and published reviews summarize animal findings involving gastric lesions, intestinal injury, fistulas, skin wounds, and other tissue-repair models.[8][9] A rat colocutaneous-fistula study reported healing changes alongside nitric oxide-system modulation.[10]

Those findings support continued laboratory investigation, but they do not prove that a 10 mg vial, a 200–600 mcg subcutaneous amount, or any specific cycle treats ulcers, inflammatory bowel disease, leaky gut, wounds, or other human conditions. The 2026 FDA review concluded that the available evidence was insufficient to characterize clinical safety for proposed routes and raised concerns about immunogenicity, peptide impurities, aggregation, and product characterization.[5]

BPC-157 Side Effects, Safety, and Regulatory Limits

A dependable list of BPC-157 side effects cannot be calculated from small human reports and animal studies. The absence of a reported event in a tiny study is not evidence that the event cannot occur. The FDA’s current assessment highlights limited safety information, possible immunogenicity for some routes, peptide-related impurities, aggregation, and difficulty characterizing the active ingredient.[5]

  • Human safety is not established: The two-participant intravenous pilot is hypothesis-generating, not a population safety trial.[4]
  • Route matters: Oral, rectal, intra-articular, intravenous, intramuscular, and subcutaneous exposures cannot be treated as interchangeable.
  • Product quality matters: Purity, counter-ion, concentration, sterility, storage, degradation, and aggregation may change experimental risk.[5]
  • Long-term risk is unknown: Repeated human administration has not been studied well enough to establish chronic safety, interaction risk, or a maximum tolerated subcutaneous dose.[1][2]
  • Approval status: BPC-157 is investigational and is not an FDA-approved drug.

BPC-157 Storage After Reconstitution

The four preparation checks above use the site’s standard mechanical wording. Storage duration still depends on the exact formulation and supplier documentation.

  • Before reconstitution: Keep the sealed lyophilized vial dry, protected from light, and at the labeled temperature.
  • After reconstitution: Refrigerate at 2–8 °C (35.6–46.4 °F) and protect from light.
  • Handling: Avoid vigorous shaking and unnecessary temperature cycling.
  • Discard date: Follow formulation-specific stability documentation. A 10 mg strength and 3 mL dilution do not establish a universal beyond-use period.

U-100 Syringe Measurements and Injection Technique

U-100 syringe units are volume markings: 100 units equals 1 mL, so one unit equals 0.01 mL. At 3.33 mg/mL, that one-unit mark contains about 33.3 mcg of BPC-157. It is not an international unit of peptide potency.

  • Use a new sterile syringe and needle for every injection and each separate vial entry.
  • Clean the vial stopper and selected skin site according to the governing laboratory or clinical procedure and allow the surface to dry.
  • Rotate subcutaneous sites rather than repeatedly using the same point.
  • Place used sharps directly into an appropriate puncture-resistant sharps container.[18]

General injection technique does not validate the compound, the displayed amount, or the route. Institutional procedures and qualified oversight remain controlling.

BPC-157 10 mg vs Other Vial Strengths

Vial strength determines how much peptide is available, not what dosage is appropriate. When the final volume stays the same, a larger vial produces a higher concentration and more peptide per U-100 unit. That is why each strength needs its own dosage chart and why copying the same syringe units across volumes would be unsafe arithmetic.

  • 10 mg at 3 mL: 3.33 mg/mL and about 33.3 mcg per U-100 unit.
  • Same amount, different concentration: The mL and unit marking must be recalculated.
  • Same peptide, same evidence limits: A different bottle size does not create new human efficacy or safety evidence.
  • Separate search intent: This page is the 10 mg calculation reference; sibling strengths should use distinct vial-specific wording while avoiding contradictory compound-level claims.

BPC-157 Dosage Questions

What is the typical BPC-157 dosage?

Online community protocols often repeat 200–600 mcg per day, which is why that range appears in the calculation chart. Published human evidence has not established it as a recommended or clinically validated dose.[1][5]

How do you mix a 10 mg vial of BPC-157?

The worked example adds 3.0 mL of bacteriostatic water to produce about 3.33 mg/mL. The four reconstitution checks show the mechanical process. Actual diluent compatibility, sterility, storage, and discard timing depend on the exact product documentation.

How many U-100 units equal 250 mcg?

At 3.33 mg/mL, 250 mcg equals approximately 0.075 mL, or 7.5 U-100 units. That is a mathematical conversion, not a dosing recommendation.

How many U-100 units equal 500 mcg?

At the same concentration, 500 mcg equals approximately 0.15 mL, or 15 U-100 units.

Is BPC-157 approved by the FDA?

No. BPC-157 is investigational, and the FDA has identified insufficient clinical safety information plus concerns about immunogenicity and product characterization.[5]

Does BPC-157 have human clinical trials?

Human evidence includes a registered oral Phase I study, small reports summarized in reviews, and a two-person intravenous pilot. None establishes the subcutaneous chart on this page as an effective human treatment protocol.[1][4][6]

Important Research Note

This page separates a transparent 10 mg vial calculation from the strength of the evidence. The 200–600 mcg rows reflect community-reported use and do not represent an FDA-approved product label, a validated human research schedule, or medical advice. Most BPC-157 benefit claims come from cell and animal research, while human safety, efficacy, interactions, and long-term outcomes remain uncertain.

BPC-157 Dosage Guide by Route and Research Question

A careful BPC-157 dosage guide separates arithmetic from evidence. Searches for injectable BPC-157, oral BPC-157, and peptide therapies often combine routes that have different absorption, sterility, and safety considerations. The published literature does not establish that a subcutaneous protocol, an oral or sublingual BPC-157 product, or BPC-157 taken orally produces equivalent exposure or clinical effects.

Some community descriptions use the phrase twice daily, while others describe daily dosing or a longer cycle length. Those conflicting dosage ranges are anecdotal. Human research does not establish a standard BPC-157 dosage, a right BPC-157 dosage based on body weight, or an optimal BPC-157 dosage for acute injuries. The chart on this page is therefore a vial-math reference, not a clinical peptide protocol.

BPC-157 Injection Dosage and Unit Math

The BPC-157 injection dosage rows show mass, volume, and U-100 syringe markings together. They do not claim that injection near the injury or subcutaneous injection near the injury accelerates healing. An injury site does not determine a validated dose. The same limitation applies to tendon and ligament injuries, muscle injuries, musculoskeletal injuries, ligament injuries, and questions about BPC-157 for tendon repair.

A BPC-157 dose can be converted mathematically only after the vial concentration is known. At 3.33 mg/mL, the displayed amounts equal 33.3 mcg per U-100 unit. Body weight is not part of that concentration calculation, and animal studies expressed as mcg per kilogram cannot be copied directly into human dosage and protocol instructions.

Questions About BPC-157 Dosage Ranges and Stacking

Is there a standard BPC-157 dosage for gut health?

No clinically validated dosage for gut health has been established. Gut and leaky gut claims rely largely on preclinical models. References to stable gastric pentadecapeptide BPC 157, body protection, blood vessel signaling, or new blood vessel formation describe research mechanisms rather than an approved human dose.

What is the difference between injectable vs oral BPC-157?

Injectable vs oral BPC-157 describes different routes. A registered oral study does not validate a subcutaneous protocol, and a calculation for injectable BPC-157 does not establish how an oral preparation should be measured.

What about BPC-157 and TB-500?

BPC-157 and TB-500 are separate investigational compounds. Combining BPC-157 with other peptides, stacking BPC-157, or using BPC-157 with TB-500 creates a different research question and does not strengthen the evidence for either compound. The related blend and stack pages keep their component calculations explicit.

Is BPC-157 a synthetic peptide?

Yes. BPC-157 is a synthetic peptide commonly described as a pentadecapeptide body protection compound. It is associated with a sequence studied in gastric research, but statements that it is found in human gastric juice should not be treated as proof of therapeutic effectiveness. BPC-157 is not FDA-approved, and safety concerns remain unresolved.

References

  • 1
    HSS Journal (2025) — Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
    View Source
  • 2
    Current Reviews in Musculoskeletal Medicine (2025) — Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
    View Source
  • 3
    Frontiers in Pharmacology (2022) — Pharmacokinetics, distribution, metabolism, and excretion of BPC157 in rats and dogs.
    View Source
  • 4
    Alternative Therapies in Health and Medicine (2025) — Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
    View Source
  • 5
    U.S. Food and Drug Administration (2026) — Pharmacy Compounding Advisory Committee briefing document for BPC-157-related bulk drug substances.
    View Source
  • 6
    ClinicalTrials.gov — NCT02637284: Phase I safety and pharmacokinetics study of oral PCO-02/BPC-157.
    View Source
  • 7
    Pharmaceuticals (2025) — Multifunctionality and Possible Medical Application of BPC-157: Literature and Patent Review.
    View Source
  • 8
    Current Pharmaceutical Design (2017) — Stable gastric pentadecapeptide BPC 157 as a therapy for tissue repair and wound healing.
    View Source
  • 9
    World Journal of Gastroenterology (2018) — Stable gastric pentadecapeptide BPC 157: from gastrointestinal tract to broader experimental healing models.
    View Source
  • 10
    Journal of Pharmacological Sciences (2008) — BPC 157 and colocutaneous fistula healing with nitric oxide-system involvement in rats.
    View Source
  • 11
    Journal of Orthopaedic Research (2010) — Pentadecapeptide BPC 157 improves ligament healing in the rat.
    View Source
  • 12
    Journal of Physiology and Pharmacology (2009) — Modulatory effect of BPC 157 on angiogenesis in muscle and tendon healing.
    View Source
  • 13
    Journal of Orthopaedic Research (2020) — BPC 157 promotes tendon-to-bone healing in a rat rotator cuff model.
    View Source
  • 14
    International Journal of Molecular Sciences (2021) — BPC 157 as a therapy for disabled myotendinous junctions in rats.
    View Source
  • 15
    International Journal of Molecular Sciences (2025) — BPC 157 after experimental quadriceps muscle-to-bone detachment in rats.
    View Source
  • 16
    Bioengineering (2024) — Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review.
    View Source
  • 17
    International Journal of Molecular Sciences (2025) — Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
    View Source
  • 18
    World Health Organization / NCBI Bookshelf — Best practices for injections and related procedures.
    View Source

Related research, protocols, and guides

Compare vial-specific calculations and review the underlying research. Each protocol remains separate because vial strength changes concentration and U-100 syringe measurements.

Research overview

Other vial-strength protocols

Related protocols

Practical guides